Bone
Authors: Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, Sarnak MJ, Hoofnagle AN, Rifkin DE, Garimella PS, Ix JH
Journal of interventional cardiology
Authors: Yap J, Singh GD, Kim JS, Soni K, Chua K, Neo A, Koh CH, Armstrong EJ, Waldo SW, Shunk KA, Low RI, Hong MK, Jang Y, Yeo KK
European journal of medicinal chemistry
Authors: Rani A, Singh A, Gut J, Rosenthal PJ, Kumar V
Journal of the American College of Radiology : JACR
Authors: Chan TM, Stukus D, Leppink J, Duque L, Bigham BL, Mehta N, Thoma B
The Journal of rheumatology
Authors: Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, Balasubramanian A, Pannacciulli N, Lin CJF, Roy-Gayos P, Bensen WG, Bensen R, Adachi JD
American journal of respiratory and critical care medicine
Authors: Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR
American journal of respiratory and critical care medicine
Authors: Matthay MA
PloS one
Authors: Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP
Bioconjugate chemistry
Authors: Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ
Volume 31 of Issue 11 | Oncology (Williston Park, N.Y.)
Authors: Ursem C, Venook AP
The first studies of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer were begun before the predictive role of RAS mutations had been elucidated. Secondary analyses of many large randomized trials have shown that mutations in exons 2-4 of KRAS and NRAS, BRAF V600E mutation, and right-sided primary tumor all predict lack of response to EGFR inhibition in the first-line setting. However, even in patient populations defined by a lack of these negative predictors, there is still not uniform response to anti-EGFR therapy. Additionally, although older adults have been shown to have the potential to both tolerate and respond to anti-EGFR therapy, the criteria for selecting the most appropriate older patients for treatment remain unclear.
View on PubMed